| Oral selinexor–dexamethasone for triple-class refractory multiple myeloma A Chari, DT Vogl, M Gavriatopoulou, AK Nooka, AJ Yee, CA Huff, ... New England Journal of Medicine 381 (8), 727-738, 2019 | 478 | 2019 |
| Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma MA Dimopoulos, D Dytfeld, S Grosicki, P Moreau, N Takezako, M Hori, ... New England Journal of Medicine 379 (19), 1811-1822, 2018 | 461 | 2018 |
| Administration of bortezomib before and after autologous stem cell transplantation improves outcome in multiple myeloma patients with deletion 17p K Neben, HM Lokhorst, A Jauch, U Bertsch, T Hielscher, B van der Holt, ... Blood, The Journal of the American Society of Hematology 119 (4), 940-948, 2012 | 441 | 2012 |
| Identification of novel mutational drivers reveals oncogene dependencies in multiple myeloma BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, FE Davies, ... Blood, The Journal of the American Society of Hematology 132 (6), 587-597, 2018 | 342 | 2018 |
| A high-risk, Double-Hit, group of newly diagnosed myeloma identified by genomic analysis BA Walker, K Mavrommatis, CP Wardell, TC Ashby, M Bauer, F Davies, ... Leukemia 33 (1), 159-170, 2019 | 331 | 2019 |
| The level of TACI gene expression in myeloma cells is associated with a signature of microenvironment dependence versus a plasmablastic signature J Moreaux, FW Cremer, T Reme, M Raab, K Mahtouk, P Kaukel, ... Blood 106 (3), 1021-1030, 2005 | 317 | 2005 |
| Lenalidomide inhibits osteoclastogenesis, survival factors and bone-remodeling markers in multiple myeloma I Breitkreutz, MS Raab, S Vallet, T Hideshima, N Raje, C Mitsiades, ... Leukemia 22 (10), 1925-1932, 2008 | 259 | 2008 |
| Multiple myeloma: patient outcomes in real‐world practice K Yong, M Delforge, C Driessen, L Fink, A Flinois, S Gonzalez‐McQuire, ... British journal of haematology 175 (2), 252-264, 2016 | 246 | 2016 |
| Progression in smoldering myeloma is independently determined by the chromosomal abnormalities del (17p), t (4; 14), gain 1q, hyperdiploidy, and tumor load K Neben, A Jauch, T Hielscher, J Hillengass, N Lehners, A Seckinger, ... Journal of clinical oncology 31 (34), 4325-4332, 2013 | 239 | 2013 |
| Targeting the BRAF V600E Mutation in Multiple MyelomaBRAF in Myeloma M Andrulis, N Lehners, D Capper, R Penzel, C Heining, J Huellein, ... Cancer discovery 3 (8), 862-869, 2013 | 233 | 2013 |
| Targeted sequencing of refractory myeloma reveals a high incidence of mutations in CRBN and Ras pathway genes KM Kortüm, EK Mai, NH Hanafiah, CX Shi, YX Zhu, L Bruins, S Barrio, ... Blood, The Journal of the American Society of Hematology 128 (9), 1226-1233, 2016 | 208 | 2016 |
| Combining information regarding chromosomal aberrations t (4; 14) and del (17p13) with the International Staging System classification allows stratification of myeloma patients … K Neben, A Jauch, U Bertsch, C Heiss, T Hielscher, A Seckinger, T Mors, ... Haematologica 95 (7), 1150, 2010 | 202 | 2010 |
| Bortezomib before and after high-dose therapy in myeloma: long-term results from the phase III HOVON-65/GMMG-HD4 trial H Goldschmidt, HM Lokhorst, EK Mai, B van der Holt, IW Blau, ... Leukemia 32 (2), 383-390, 2018 | 191 | 2018 |
| STIL is required for centriole duplication in human cells J Vulprecht, A David, A Tibelius, A Castiel, G Konotop, F Liu, F Bestvater, ... Journal of cell science 125 (5), 1353-1362, 2012 | 186 | 2012 |
| Phase III trial of bortezomib, cyclophosphamide and dexamethasone (VCD) versus bortezomib, doxorubicin and dexamethasone (PAd) in newly diagnosed myeloma EK Mai, U Bertsch, J Dürig, C Kunz, M Haenel, IW Blau, M Munder, ... Leukemia 29 (8), 1721-1729, 2015 | 181 | 2015 |
| Elotuzumab in combination with lenalidomide and dexamethasone in patients with relapsed multiple myeloma: final phase 2 results from the randomised, open-label, phase 1b–2 dose … PG Richardson, S Jagannath, P Moreau, AJ Jakubowiak, MS Raab, ... The Lancet Haematology 2 (12), e516-e527, 2015 | 146 | 2015 |
| The immunogenic glycoprotein gp35-37 of human herpesvirus 8 is encoded by open reading frame K8. 1 MS Raab, JC Albrecht, A Birkmann, S Yağuboğlu, D Lang, ... Journal of virology 72 (8), 6725-6731, 1998 | 141 | 1998 |
| Delineation of distinct subgroups of multiple myeloma and a model for clonal evolution based on interphase cytogenetics FW Cremer, J Bila, I Buck, M Kartal, D Hose, C Ittrich, A Benner, MS Raab, ... Genes, Chromosomes and Cancer 44 (2), 194-203, 2005 | 139 | 2005 |
| Targeting PKC in multiple myeloma: in vitro and in vivo effects of the novel, orally available small-molecule inhibitor enzastaurin (LY317615. HCl) K Podar, MS Raab, J Zhang, D McMillin, I Breitkreutz, YT Tai, BK Lin, ... Blood 109 (4), 1669-1677, 2007 | 137 | 2007 |
| Expression of EGF-family receptors and amphiregulin in multiple myeloma. Amphiregulin is a growth factor for myeloma cells K Mahtouk, D Hose, T Rème, J De Vos, M Jourdan, J Moreaux, G Fiol, ... Oncogene 24 (21), 3512-3524, 2005 | 134 | 2005 |
